Guidance: Adrenaline Auto-Injectors (AAIs) safety campaign

⌂Back To Homepage Subscribe To RSS Feed

Medicines Healthcare Products Regulatory Agency

April 24

13:28 2023

Print This Article Share it With Friends

Created by Medicines Healthcare Products Regulatory Agency 0 comments

Adrenaline Auto-Injectors (AAIs)

HTML

The correct use of your Adrenaline Auto-Injector (AAI)

PDF, 1.05 MB, 1 page

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email webupdates@mhra.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Y defnydd cywir och Chwistrellydd Adrenalin Awtomatig (AAI)

PDF, 1.05 MB, 1 page

This file may not be suitable for users of assistive technology.

Request an accessible format.

Details

AAIs (sometimes referred to by their product name i.e., Epipen or Emerade) are licensed medicinal products that deliver adrenaline by means of an auto-injector device for the emergency treatment of anaphylaxis, a life-threatening severe allergic reaction.

Published 24 April 2023

Your name:	Your email:
Comments:
Post my comment

GovWire